Degenerative disease

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Retrieved on: 
Friday, December 2, 2022

Webcast / Conference Call Information:

Key Points: 
  • Webcast / Conference Call Information:
    The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the Webinar ID: 815 1815 0021 reference passcode 279853.
  • A replay of the conference call will also be available on Anavexs website for up to 30 days.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option will have a per share exercise price equal to the closing price of a share of Better Therapeutics common stock on the Grant Date.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases.
  • Better Therapeutics clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune disease.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn .

'Tis the Season for Giving Back at Jim Ellis Automotive

Retrieved on: 
Friday, December 2, 2022

ATLANTA, Dec. 2, 2022 /PRNewswire-PRWeb/ -- The Jim Ellis Automotive Group is pleased to announce their seventh annual holiday giving campaign supporting Children's Healthcare of Atlanta. Starting December 1, 2022 through December 31, 2022, each of the 20 Jim Ellis family-owned and operated dealerships will donate a portion of every sale of all new or pre-owned vehicles to The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.,

Key Points: 
  • Jim Ellis Automotive Group launches annual holiday giving campaign to support the fight against pediatric cancer and blood disorders.
  • ATLANTA, Dec. 2, 2022 /PRNewswire-PRWeb/ -- The Jim Ellis Automotive Group is pleased to announce their seventh annual holiday giving campaign supporting Children's Healthcare of Atlanta.
  • Through their efforts over all of the holiday giving campaigns, Jim Ellis Automotive has donated over $250,000 to groups supporting women and children in need across the Atlanta area.
  • "No one wants to see a child struggle or be in pain" said Jim Ellis Automotive Group Vice President Stacey Ellis Hodges.

Medical Tubing Global Market Report 2022: Trend Shift Toward Preventative Healthcare Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Medical Tubing Market Size, Share & Trends Analysis Report by Product (Silicone, Polyolefins), by Application (Bulk Disposable Tubing, Catheters), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Tubing Market Size, Share & Trends Analysis Report by Product (Silicone, Polyolefins), by Application (Bulk Disposable Tubing, Catheters), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global medical tubing market size is expected to reach USD 19.50 billion by 2030.
  • The market is expected to expand at a CAGR of 5.7% from 2022 to 2030.
  • The growing middle-class population and healthcare facilities have changed the attitude of consumers toward preventive healthcare, which is expected to augment the demand for medical devices, including medical tubing, over the forecast period.

Announcing Andrew A. Wilson MD as the Alpha-1 Foundation's new Scientific Director

Retrieved on: 
Friday, December 2, 2022

CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.

Key Points: 
  • CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.
  • Dr. Wilson assumes this role with a long-standing passion and commitment to the Alpha-1 community.
  • "I am honored and humbled to have been selected as the new Scientific Director of the Alpha-1 Foundation.
  • I hope that as Scientific Director I will be able to help the Foundation to advance its mission and work towards a cure for AATD."

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
Friday, December 2, 2022

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Global Bacteriophage Therapy Market Report 2022: Looming Threat of Antimicrobial Resistance Drives Research & Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • Given the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies.
  • In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating bacteriophage therapy have increased at a growth rate of more than 30% over the last few years.
  • With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapy market to witness notable growth in the mid to long term.

Global Nutrigenomics Market Report 2022 to 2035: Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Nutrigenomics Market by Type of Sample, Type of Sample Collection Method and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nutrigenomics Market by Type of Sample, Type of Sample Collection Method and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current landscape and future potential of the nutrigenomics focused companies.
  • The study features an in-depth analysis, highlighting the capabilities of nutrigenomics focused companies.
  • How is the current and future market opportunity likely to be distributed across key segments?

Huntington Medical Research Institutes to Host Holiday Open House Commemorating 70th Anniversary

Retrieved on: 
Friday, December 2, 2022

Huntington Medical Research Institutes (HMRI), a leading biomedical research organization in Southern California, is celebrating its 70th anniversary by opening its doors to the public this Saturday, December 3, 2022, from 11 a.m. to 3 p.m. for its Holiday Open House.

Key Points: 
  • Huntington Medical Research Institutes (HMRI), a leading biomedical research organization in Southern California, is celebrating its 70th anniversary by opening its doors to the public this Saturday, December 3, 2022, from 11 a.m. to 3 p.m. for its Holiday Open House.
  • We look forward to celebrating many more innovative discoveries in our focus areas of cardiovascular, neurovascular and neuroscience research.
  • HMRI began as an outgrowth of two separate institutes: Pasadena Foundation for Medical Research, established in 1952, and the Institute of Medical Research of Huntington Memorial Hospital, founded in 1953.
  • Huntington Medical Research Institutes (HMRI) is an independent, nonprofit organization located in Pasadena, California.